Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--May 1, 2025-- Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has out-licensed its discovery platforms, including certain platform and program intellectual property, to